Slide 1: GeneDx Q1 2026 Earnings Presentation
GeneDx Nasdaq: WGS Q1 2026 Earnings Presentation May 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our future performance and our market
Slide 3: Q1 2026 Results
Q1 2026 Results Metric First Quarter 2026 Revenue1 $102.3 million Growth in exome and genome volume 34% Growth in exome and genome revenue 27% Adjusted gross margin1 69% Adjusted net loss1 $(8.2 million) Cash on hand $171.7 million 1 Adjusted gross margin and adjusted net loss are non-GAAP financial
Slide 4: Strong demand drove exome and genome volume growth
Strong demand drove exome and genome volume growth Exome and genome volume Exome and Genome Volume year-over-year: 27,488 30,000 • Q1 2026 YoY: up 34% to 25,000 27,488 20,562 20,000 16,592 • Majority of growth driven by 15,000 foundational markets of geneticists and pediatric 10,000 neurologists 5,0
Slide 5: Exome and genome revenue growth impacted by reimbursement and mix
Exome and genome revenue growth impacted by reimbursement and mix Exome and Genome Revenue (in $M) Exome and genome revenue $120 year-over year: $90.6 $100 • Q1 2026 YoY: up 27% to $90.6M $80 $71.4 • Q1 ARR: ~$3,300 $60 $44.0 • Blended ARR lower due to $40 higher genome mix and lower parental sample
Slide 6: 2026 Guidance Update
2026 Guidance Update Full Year 2026 Full Year 2026 Second Quarter of 2026 Metric Previous Guidance Updated Guidance Guidance February 23, 2026 May 4, 2026 May 4, 2026 Revenue $540 to $555 million $475 to $490 million $110 to $112 million Growth in exome and 33% to 35% At least 30% ~30,000 tests geno
Slide 7: Q1 and Full Year 2026 Revenue Bridge
Q1 and Full Year 2026 Revenue Bridge Q1 2026 Revenue ($M) FY 2026 Revenue Guidance ($M) $120 Expected: $114M Actual: $102M $575 Previous: $540–$555M Revised: $475–$490M $115 $114 $(5.5) $550 $540 $(36) $110 $(2.5) $525 $(2) $(11) $(2) $105 $500 $(6) $102 $(6) $(6) $475 $100 $475 $95 $450 $90 $425 Ex
Slide 8: Sharpening financial focus for the balance of 2026
Sharpening financial focus for the balance of 2026 Improving blended ARR by actively managing test 1 Channel Management mix to focus on healthy unit economics 2 Revenue Cycle Accelerating market access and revenue cycle investments 3 Genome COGS Optimizing cost per test for genome by advancing ongoi
Slide 9: Organizing the company around three key imperatives
Organizing the company around three key imperatives Grow utilization of Optimize unit Deliver the leading exome and genome economics products at unmatched scale 9
Slide 10: Appendix
Appendix 10 Confidential & Proprietary. Do Not Distribute.
Slide 11: Empowering everyone to live their healthiest life through genomics
Empowering everyone to live their healthiest life through genomics 11
Slide 12: GeneDx is the global leader in rare disease diagnosis
GeneDx is the global leader in rare disease diagnosis The #1 genetic test GeneDx InfinityTM Experience & Technology Preferred by 80% of geneticists The largest and most diverse Diagnosing more rare disease and granted FDA Breakthrough rare disease dataset to deliver patients than anyone else and Dev
Slide 13: Supercharging growth to serve more patients globally
Supercharging growth to serve more patients globally Number of Exomes & Genomes 2026+ Expanding commercial team and entering new markets 1 Million Added 30% more tests to Infinity in 2025 than in the prior 24 years combined 750K 2025 AAP guidelines opened general pediatrics 500K 2017 Launched genome
Slide 14: An accurate genetic diagnosis is key to transforming healthcare
An accurate genetic diagnosis is key to transforming healthcare Enabling precision Providing an early Fueling genomic and accurate drug medicine genetic diagnosis discovery 14
Slide 15: Delivering the future of precision medicine via the network effect
Delivering the future of precision medicine via the network effect Patients Biopharma Delivering faster, more accurate diagnosis Accelerating drug discovery, enabling with personalized treatments based on clinical trials, and unlocking biomarkers for biology, leading to better outcomes targeted ther
Slide 16: Trusted by the nation's leading health systems
Trusted by the nation’s leading health systems 16
Slide 17: GeneDx Infinity is the largest and most diverse rare disease dataset
GeneDx InfinityTM is the largest and most diverse rare disease dataset ~1M >2.5M The most accurate exomes & genetic diagnosis genomes tests 2x the answers compared to public datasets >8M >8M Greatest scale advantage health phenotypic datapoints Fastest diagnosis and records most efficient operations
Slide 18: Our AI strategy accelerates the flywheel effect of our data
Higher diagnostic yields and more Additional Our AI strategy accelerates answers patients tested the flywheel effect of our data ELS OD M E M G A A U C The compounding power of the data G H IN AN from each new patient informs more E LARGE L LEA diagnoses and extends our lead RNING Proprietary AI mod
Slide 19: This large and ever-growing opportunity is ours to win
This large and ever-growing opportunity is ours to win Upside Opportunities International, Biopharma/Data, Precision Medicine Adult $20B Adult Neurologists, Adult Cardiologists, and Other Specialists Pediatrics & Rare Pediatric Specialists, Pediatricians, $25B NICU, Prenatal, and gNBS 19
Slide 20: On average, an accurate diagnosis takes 5 years
On average, an accurate diagnosis takes 5 years The economic burden of rare diseases in the U.S. is over $1 trillion annually Referral to a No diagnosis Visit primary care specialist physician Genetic testing (CMA) GeneDx provides First answers in symptom Online Another months research specialist Or
Slide 21: Payor coverage for exome and genome sequencing is expanding
Payor coverage for exome and genome sequencing is expanding 〉 GeneDx is contracted with 80% of covered lives, including all large national commercial payers 〉 Medicaid and commercial insurance coverage continues to grow for exome and genome o 38 states cover exome or genome testing o 17 states cover
Slide 22: Medicaid programs across the country are expanding access
Medicaid programs across the country are expanding access Current Medicaid Coverage Landscape Exome or Genome Sequencing Rapid Genome Sequencing Both No Coverage New or Enhanced Coverage 22 1. GeneDx Internal Data, data on file 2026
Slide 23: Our north star is to diagnose as many people as fast as possible
Our north star is to diagnose as many people as fast as possible 23
Slide 24: Our stacked, compounding growth strategy unlocks new opportunities
Our stacked, compounding growth strategy unlocks new opportunities Three layers, multiple building blocks to sustained high growth with disciplined expansion plan Future • gNBS Markets • New Channels (Developing) • BioPharma & Data Expansion • General Pediatricians (H2 2026) • NICU (since 2024) Mark
Slide 25: Large growth opportunities ahead to deepen penetration and expand our footprint
Large growth opportunities ahead to deepen penetration and expand our footprint Clinician Penetration by Market Patient Penetration by Market 100% 100% 90% 90% 80% 80% 70% 70% 60% 60% 50% 50% 40% 40% 30% 30% 20% 20% 10% 10% 0% 0% Geneticsits Pediatric Geneticists Prenatal NICU Adult General Genetics
Slide 26: Entering new markets to deliver answers at the earliest moment possible
Entering new markets to deliver answers at the earliest moment possible Standard of care: years of disease progression Prenatal NICU Pediatrician Pediatric Geneticist Adult Specialist Specialist 26
Slide 27: Geneticists remain key customers and prefer GeneDx
Foundational Market Geneticists remain key customers and prefer GeneDx Geneticist recommendations reinforce our leadership in new markets Leading position: 80% market share driven by superior accuracy, broad access, and cutting-edge discovery Continued growth: Largest contributor to revenue today wi
Slide 28: Pediatric specialists continue drive high growth
Foundational Market Pediatric specialists continue drive high growth Increased ordering and new customer activation driving expansion Significant share: Over 30% of pediatric neurologists now order from us with continued growth ahead Strong awareness: Greatest brand recognition of any genetics lab -
Slide 29: Pediatricians are becoming the new front line of genomic medicine
Expansion Pediatricians are becoming the new front line of Market genomic medicine First mover to an untapped market with the #1 genetic test in hand Massive market: 600K patients diagnosed with DD/ID by 25K pediatricians annually Trusted partner & clear leader: Leading product, wraparound services,
Slide 30: The NICU is an untapped opportunity for early intervention and improved outcomes
Expansion Market The NICU is an untapped opportunity for early intervention and improved outcomes Taking a protocol-driven approach to benefit more patients and lower healthcare costs Large unmet need: Up to 60% NICU patients could benefit from rWGS per SeqFirst (~235k patients) but less than 5% of
Slide 31: GenomeDx Prenatal extends our industry-leading diagnostic capabilities into prenatal care
Expansion GenomeDx Prenatal extends our industry-leading Market diagnostic capabilities into prenatal care Setting a new standard for prenatal genomic diagnoses Large unmet need: For patients with structural anomalies on prenatal ultrasound, impacting up to 4% of pregnancies Extensive prenatal exper
Slide 32: Adult specialists will unlock future growth and impact
Expansion Market Adult specialists will unlock future growth and impact Putting commercial focus behind the organic growth in adult exome and genome testing New market: Expanding to neurologists in 2026 with a focus on clinicians already ordering genetic testing Green space: Strong demand and reimbu
Slide 33: Global reach with decentralized testing powered by GeneDx Infinity
Expansion Global reach with decentralized testing powered by Market centralized intelligence from GeneDx InfinityTM Cloud-native platform enables remote interpretation while complying with local regulations Expanded international footprint with sales reps in key geographies Providing leading interpr
Slide 34: Transforming healthcare from diagnostic odyssey to day one action with gNBS
Future Transforming healthcare from diagnostic odyssey to Market day one action with gNBS GeneDx has the evidence, experience, and operational capabilities to lead global adoption Evidence Experience Capabilities Data from the GUARDIAN study: • Sequenced >22,000 newborns • Flexible services – from e
Slide 35: Pioneering new channels and partnerships to deliver on the promise of precision genomic medicine
Future Pioneering new channels and partnerships to deliver Market on the promise of precision genomic medicine 35
Slide 36: Deploying the most comprehensive, longitudinal dataset for rare disease ever assembled
Future Deploying the most comprehensive, longitudinal Market dataset for rare disease ever assembled Genetic data Claims Electronic Prescription health records Patient Imaging demographics Unlocking faster HEOR, biopharma innovation, and AI-driven discovery 36
Slide 37: Transforming every stage of drug development
Transforming every stage of drug development Research & Clinical Launch & Market Authorization Development Trials Post-Marketing & Access Target Validation Patient Matching Diverse Commercialization & Modeling & Recruitment Longitudinal Data 37
Slide 38: Turning insight into biopharma impact
Turning insight into biopharma impact 38
Slide 39: Proven leadership driving high-growth and operational excellence at scale
Proven leadership driving high-growth and operational excellence at scale Katherine Stueland Kevin Feeley Bryan Dechairo Melanie Duquette Chief Executive Officer Chief Financial Officer Chief Operating Officer Chief Growth Officer Lisa Gurry Heidi Chen Linda Genen Jami Biliboaca Chief Business Offic
Slide 40: A rare opportunity to transform healthcare fueled by unmatched data and momentum
A rare opportunity to transform healthcare fueled by unmatched data and momentum Massive TAM and expanding Emerging guidelines and serviceable market improving payer landscape Leadership position Scale advantage Differentiated technology Proven management team 40
Slide 41: GeneDx enables a future that is predictive, preventative, and ultimately curative
GeneDx enables a future that is predictive, preventative, and ultimately curative. That future always begins with a single answer. And that answer changes everything. 41
Slide 42: Reconciliation of non-GAAP financial measures
Reconciliation of non-GAAP financial measures Adjusted gross profit1, adjusted gross margin, and adjusted net (loss) income (in $ thousands) Three months ended March 31, 2026 2025 GeneDx Other2 Total GeneDx Other2 Total Revenue $ 101,496 $ 758 $ 102,254 $ 87,115 $ – $ 87,115 Adjusted cost of service